• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Retrophin Inc

+ Add to Watchlist

RTRX:US

12.9200 USD 0.1900 1.49%

As of 17:10:00 ET on 12/24/2014.

Snapshot for Retrophin Inc (RTRX)

Open: 12.7500 Day's Range: 12.5300 - 12.9850 Volume: 197,743
Previous Close: 12.7300 52wk Range: 6.6600 - 24.2500 1-Yr Rtn: +73.42%

Stock Chart for RTRX

No chart data available.
  • RTRX:US 12.9200
  • 1D
  • 1M
  • 1Y
12.7300
Interactive RTRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RTRX

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -4.4743
Est. EPS (USD) (12/2014) -
Est. PEG Ratio -
Market Cap (M USD) 344.96
Shares Outstanding (M) 26.70
30 Day Average Volume 563,714
Price/Book (mrq) -
Price/Sale (ttm) 24.0122
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RTRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RTRX

Retrophin, Inc. is a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. The Company is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases.

Stephen J Aselage "Steve"President/CEO/COOHoracio PlotkinChief Medical Officer
Laura M ClagueSenior VP/CFOMargaret E Valeur-JensenGeneral Counsel
More Company Profile & Key Executives for RTRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil